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Abstract
Background: The identification of the signals that should be provided by antigen-presenting cells (APCs) to induce a CD8
+ T
cell response in vivo is essential to improve vaccination strategies using antigen-loaded APCs. Although dendritic cells have
been extensively studied, the ability of other APC types, such as B cells, to induce a CD8
+ T cell response have not been
thoroughly evaluated.
Methodology/Principal Findings: In this manuscript, we have characterized the ability of CD40-activated B cells, stimulated
or not with Toll-like receptor (TLR) agonists (CpG or lipopolysaccharide) to induce the response of mouse naı ¨ve CD8
+ T cells
in vivo. Our results show that CD40-activated B cells can directly present antigen to naı ¨ve CD8
+ T cells to induce the
generation of potent effectors able to secrete cytokines, kill target cells and control a Listeria monocytogenes infection.
However, CD40-activated B cell immunization did not lead to the proper formation of CD8
+ memory T cells and further
maturation of CD40-activated B cells with TLR agonists did not promote the development of CD8
+ memory T cells. Our
results also suggest that inefficient generation of CD8
+ memory T cells with CD40-activated B cell immunization is a
consequence of reduced Bcl-6 expression by effectors and enhanced contraction of the CD8
+ T cell response.
Conclusions: Understanding why CD40-activated B cell immunization is defective for the generation of memory T cells and
gaining new insights about signals that should be provided by APCs are key steps before translating the use of CD40-B cell
for therapeutic vaccination.
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Introduction
T cells recognize via their specific T cell receptor (TCR) a
peptidic fragment of the antigen (Ag) in association with MHC
molecules presented at the surface of Ag-presenting cells (APCs).
Following Ag encounter, T cells undergo massive proliferation and
differentiate into effector T (Te) cells. After elimination of the
pathogen or tumor, most Te cells die by apoptosis while a few
differentiate into memory T (Tm) cells providing long term
protection against re-infection or tumor relapse. The success of
vaccination is dependent on the generation and long-term
maintenance of functional Ag-specific Tm cells. However, little
is known about the signals that should be provided by APCs to
promote Tm cell development.
Efficient priming of naı ¨ve CD8
+ T cells depends on the
provision by APCs of three key signals to T cells. First, APCs
should present, embedded in their major histocompatibility
complex (MHC) class I molecules, a peptidic fragment of the
Ag. Second, co-stimulation via CD80 and CD86 expressed by
APCs is essential to induce naı ¨ve CD8
+ T cell response. Third,
inflammatory signals, such as interleukin (IL)-12 or type I
interferons (IFNs), are necessary to induce an optimal response
of CD8
+ T cells [1]. Furthermore, several other molecules
expressed by APCs have been shown to influence CD8
+ T cell
response. Among those, cytokines, costimulatory molecules of the
tumor necrosis factor (TNF) family, Notch ligands and adhesion
molecules have been shown to play a role at different stages of the
T cell response. However, the exact signals that should be
provided by APCs to induce efficient generation of CD8
+ Tm cells
are still unknown. This knowledge is crucial to improve
vaccination strategy and to better define the type of APCs that
should be used for therapeutic vaccination.
Several studies have shown that vaccination with Ag-pulsed
dendritic cells (DCs) is very efficient to promote the development of
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+ Tm cells [2,3]. Very interestingly,
CD8
+ Tm cell generation is accelerated with DC vaccination when
compared to immunization with live pathogens [2]. This is mostly
due to the low level of inflammation that promotes the formation of
memory precursor effector cells (MPECs) expressing high level of
CD127 and low level of KLRG1 [2–4]. The excellent Ag
presentation capability of DCs and their powerful ability to prime
naı ¨ve T cells have put these cells at the forefront of therapeutic
vaccination strategies to treat cancer or infected patients. However,
this approach has not been extremely successful yet. Furthermore,
DCs are present in very low number in peripheral blood which
limits their use [5].Therefore, investigatingthe ability of other more
abundant APC types, such as activated B cells, to induce a CD8
+ T
cell response might help to design better vaccination strategy and to
gain knowledge about the signals that APCs should provide for the
development of CD8
+ Tm cells.
Little is known on the potential of other APCs, such as B cells, to
induce the generation of Te and Tm cells. Previous studies have
shown that immunization with naı ¨ve resting B cells induce T cell
unresponsivenessinnaı ¨veCD4
+[6–12]and CD8
+Tcells[11].This
tolerance induction probably results from poor expression of co-
stimulatorymolecules bynaı ¨veB cells.Although activation of B cells
with LPS induced expression of CD80 and CD86, this was not
sufficient to induce T cell priming [11,13] indicating that other
signals should be provided to B cells. More recent studies have
shown that human CD40-activated B (CD40-B) cells are very good
at inducing Ag-specific CD4
+ and CD8
+ T cell response in vitro [14–
17]. Indeed, these CD40-activated B cells express high levels of co-
stimulatory ligands, major histocompatibility (MHC) class I and
class II molecules [14,18,19], CD62L and have the ability to
migrate to secondary lymphoid organs [19–21]. These character-
istics suggest that these cells might be very efficient to induce the
response of naı ¨ve CD8
+ T cells in vivo. In addition, the possibility to
expand these cells in large number from peripheral blood [20]
renders them even more attractive to use in vaccination protocol.
In this manuscript, we have characterized the ability of CD40-B
cells, stimulated or not with Toll-like receptor (TLR) agonists to
induce the response of naı ¨ve CD8
+ T cells in vivo. Our results show
that CD40-B cells can directly present Ag to naı ¨ve CD8
+ T cells to
induce the generation of potent effectors able to secrete cytokines,
kill target cells and control a Listeria monocytogenes (Lm) infection.
However, CD40-B cell immunization did not lead to the proper
formation of CD8
+ Tm cells. Although maturation of CD40-B
cells with TLR agonists increased the number of Ag-specific T
cells generated it did not promote the development of CD8
+ Tm
cells. Understanding why CD40-B cell immunization is defective
for the generation of Tm cells and gaining new insights about
signals that should be provided by APCs are key steps before
translating the use of CD40-B cell for therapeutic vaccination.
Materials and Methods
Mice
B6SJL, C57BL/6 and OT-1 [22] mice were bred at the
Maisonneuve-Rosemont Hospital Research Center facility. Bm1
mice (B6.C-H2K
bm1/ByJ) were purchased from the Jackson
Laboratory. Mice were housed in a pathogen-free environment
andtreatedinaccordancetotheCanadianCouncilonAnimalCare
guidelines. Our animal protocol (number: 2007-36) was approved
by the Hospital Maisonneuve-Rosemont Council on Animal Care.
B cell and DC cultures
For B cell culture, lymphocytes were isolated on a FICOLL
gradient from male C57BL/6 or B6SJL spleen followed by a 4
days culture on irradiated fibroblasts stably transfected with the
CD40L cDNA (3T3-CD40L) [23] to generate CD40-B cells.
Bone-marrow derived DC were generated as previously described
[3]. The day before harvesting, lipopolysaccharide (LPS) (1 mg/ml)
or CpG-DNA (2 mM) was added to cultures. The ovalbumin
(OVA)257–264 peptide (SIINFEKL) or an irrelevant peptide
(SIYRYYGL) (Midwest biotech) was loaded overnight on DCs
(2 mg/ml) and B cells (4 mg/ml) on the last day of culture.
Immunization and analysis of T cell response
Two days after adoptive transfer of 10
6 OT-1 T cells (CD45.2
+;
from female mice) into female B6SJL mice (CD45.1
+), recipients
were immunized i.v. with 0.5–2610
6 DCs or 2–6610
6 CD40-B
cells (from male mice to induce a CD4 T cell response against the
male minor histocompatitbility antigen HY [24]) as indicated in
figure legends. The presence of Te (d4 post-immunization) and
Tm (d30/45 post-immunization) cells were evaluated in the same
mouse by sequential removal of superficial lymph nodes as
described previously [3]. The presence of Tm cells in tertiary sites
and effector functions were analyzed as previously described [3].
Te and Tm cells were identified by flow cytometry as being CD8
+
and CD45.2
+. For immunization of Bm1 mice, 5610
6 CFSE-
labelled OT-1 T cells were adoptively transferred in the morning
and immunization were realized at least 5 h later. Mice were
immunized either with 6610
6 CD40-B cells or 2610
6 DC
matured with LPS and loaded or not with OVA257–264. OVA-
specific T cells were identified using K
b-OVA tetramer staining.
Abs, cytometry, and cell sorting
Anti-CD86 (GL-1), -CD8 (53-6.7), -Ly6C (AL-21), CD122
(5H4) and -Bcl-2 (A19-3) were purchased from BD Biosciences.
Anti-H2-K
b (AF6-88.5), -CD40 (IC10), -CD45.2 (104), -CD44-
APC-Cy7 (1M7), -CD8 (53-6.7), CD19 (6D5), -CD11c (N418), -
NK1.1 (PK136), CD27 (LG.3A10), CD80 (16-10A1), CD43
(1B11) and -IL-2 (JES6-5H4) were purchased from Biolegend.
Anti- I-A
b (28-16-8S), -CD62L (MEL-14) and -CD11b (M1/
70.15) were purchased from Caltag Laboratories. Anti-CD127
(A7R34), -Eomes-Alexa-647 (Dan11mag) and -granzyme B-PE
(16G6) were purchased from eBioscience. Anti-Bcl-6-PE (7D1)
and -T-bet-PE (4B10) were purchased from Santa Cruz Biotech-
nology. Anti-IFN-c-FITC (XMG1.2) was purchased from Invitro-
gen. OVA peptide loading on K
b MHC was measured by staining
with the 25-D1.16 Ab [25] followed by staining with a rat anti-
mouse IgG1-PE (A85-1) antibody purchased from BD Bioscience.
The H2K
b-OVA monomers were purchased from CANVAC
tetramer core facility and tetramers were generated using
extravidin-PE. Cell surface stainings and intracellular stainings
for cytokine were performed as previously described [3,26]. Bcl-6
and Eomes intracellular stainings were performed with the FoxP3
kit from eBioscience while T-bet staining was done with the
cytofix/cytoperm kit from BD Bioscience. For Bcl-2 staining, cells
were stained for 30 minutes in 0.1% saponin (Sigma-Aldrich) and
washed twice without saponin before cell surface staining. In some
experiments, CD40-B LPS cells were sorted before immunization.
Cells were stained with anti-CD11b, anti-NK1.1 and anti-CD11c
Abs. Negative cells (B cells) were sorted on a FACSVantage and
injected into mice.
In vivo killing assay
At d4 post-immunization, equal numbers (10
7) of B6.SJL
splenocytes loaded or not with the OVA peptide and differentially
stained with CFSE (250 nM or 25 nM respectively) were injected
i.v. into immunized mice. 4 h later, the percentage of in vivo killing
was determined as described previously [27]. The percentage of
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low/percentage CFSE high), and percentage of specific ly-
sis=[12(ratio unprimed/ratio primed)]6100.
Listeria monocytogenes (Lm) challenge
Lm was grown as previously described [28]. One lethal dose
(10
5 bacteria) of Lm expressing OVA was injected i.v. Three days
post-infection, spleen and liver were harvested, homogenized,
diluted and plated onto brain hearth infusion (BHI) plates
containing streptomycin. After 24 h of incubation at 37uC,
CFU/g of organ was determined.
Quantitative real-time PCR
Total RNA was isolated using TRIzol (Invitrogen). RNA were
reverse transcribed into cDNA using Superscript II with oligo(dT)
primers (Invitrogen) as previously described [26]. Real-time PCR
were performed in triplicates using SYBR Green (Invitrogen) on
an Applied Biosystems 7500 Real Time PCR system. PCR was
performed with mouse Blimp-1 primers: forward, 59-ACA CAC
AGG AGA GAA GCC ACA TGA-39 and reverse, 59TCG AAG
GTG GGT CTT GAG ATT GCT-39. The primers for the
internal control hypoxanthine guanine phosphoribosyl transferase
(HPRT) were: forward, 59-CTC CTC AGA CCG CTT TTT
GC-39 and reverse, 59-TAA CCT GGT TCA TCA TCG CTA
ATC-39 [29]. The DCT value for each sample was determined by
calculating the difference between the CT value of the target and
the CT value of the endogenous reference gene (HPRT). Then, the
DDCT value for each sample was determined by subtracting the
mean of DCT value of the sample from the DCT value of a
reference sample composed of cDNA from brain, thymus, spleen,
activated splenocytes (anti-CD3 and anti-CD28), EL4 cell line,
D011.10 cell line and SAMBOK cell line. The relative level of
target gene expression was calculated using 2
2DDCT.
Statistical analysis
Statistical analyses for differences between groups were
performed using one-way ANOVA followed by Games-Howell
post-tests (3 experimental groups or more) or Student’s T-test (two
experimental groups). Data are presented as mean +/2 SEM. All
tests were two-sided and p,0.05 was considered statistically
significant.
Results
CD40-B cell immunization efficiently generates effector
CD8
+ T cells but not memory
We tested if activation of B cells with CD40L and further
maturation with different TLR agonists generated APCs able to
induce an in vivo CD8
+ T cell response. Splenocytes were activated
and expanded on fibroblasts expressing CD40L and then LPS or
CpG DNA was added to stimulate TLR4 or TLR9 respectively
(hereafter referred to as CD40-B LPS and CD40-B CpG). CD40
engagement on B cells resulted in up-regulation of the costimu-
latory molecules CD80 and CD86 but CD40-B LPS cells bore a
greater activated state when compared to CD40-B and CD40-B
CpG cells. (Figure 1 and Figure S1). The expression of CD62L
and CD40 was similar in all conditions (Figure 1 and Figure S1).
Furthermore, the expression of K
b and I-A
b MHC molecules was
comparably up-regulated in the three groups of CD40-B cells
(Figure 1 and Figure S1).
Next, we evaluated the ability of our different CD40-B cell
cultures to prime CD8
+ T cell response in vivo. To do so, we
adoptively transferred 10
6 naı ¨ve OVA-specific OT-1 CD8
+ T cells
followed by immunization with 2610
6 CD40-B, CD40-B CpG or
CD40-B LPS cells pulsed with the OVA peptide. As shown in
Figure S1, peptide loading was equivalent in the three groups of
CD40-B cells. To provide T cell help, an endogenous anti-male
response by CD4
+ T cells was generated by immunizing female
recipients, transferred with female OT-1 T cells, with male APCs.
The CD8
+ T cell response obtained after CD40-B cell immuni-
zation was always compared to the one obtained with LPS-
activated DCs. Our results show that immunization with CD40-B
cells allows for the generation of CD8
+ Te cells (Figure 2A and B).
However, CpG or LPS activation of CD40-B cells increases the
number of Te cells (Figure 2A and B), although 2-fold less than
DC immunization. We were also able to induce the response of
endogenous CD8
+ T cells (without the adoptive transfer of OT-1
T cells) to OVA using tetramer staining following CD40-B cell
immunization (Figure S2).
Most strikingly, CD40-B cells matured or not with TLR ligands
were almost always unable to induce CD8
+ Tm cell development
while DC immunization led to efficient CD8
+ Tm cell generation
(Figure 2A–D). Similar results were obtained in the spleen,
peritoneum and bone marrow (not shown). The lack of Tm cell
generation with CD40-B cell immunization is not a consequence
of the reduced number of Te cells generated since Tm cells were
also efficiently generated when we immunized with less DCs
(Figure S3), which led to the production of less effectors. In few
experiments, some CD8
+ Tm cells were generated following
CD40-B cell immunization. However, the yield of Tm cell
generation was always very low (Figure 2C). None of the mice
immunized with CD40-B LPS or CD40-B CpG cells developed
significant number of Tm cells (at least 5% of effectors; Figure 2D)
Figure 1. CD40-B cells have an activated phenotype. After 3 d of
culture on murine 3T3-CD40L fibroblasts, CD40-B cells were matured or
not with LPS (1 mg/mL) or CpG (2 mM) for 24 h (CD40-B LPS and CD40-
B CpG). Freshly isolated splenocytes were used as a naı ¨ve B cell control.
The histogram bars show the mean of fluorescence intensity (MFI) +/2
standard deviation of the mean (SEM) for the expression of CD86, CD80,
CD62L, CD40, K
b and I-A
b gated on the CD19
+ population. The results
are pooled from at least three independent experiments except for
CD40 expression on B cells (n=2). * p,0.05, ** p,0.01 and ***
p,0.001.
doi:10.1371/journal.pone.0030139.g001
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+ T cell response. A. CD40-B cell vaccination generates CD8
+ Te cells but
not Tm cells. 10
6 female OT-1 T cells (CD8
+CD45.2
+) were adoptively transferred into congenic B6SJL female mice (CD45.1
+) followed by immunization
two days later with 2610
6 CD40-B cells, matured or not with LPS (1 mg/mL) or CpG (2 mM) and loaded with 4 mg/mL OVA or with an irrelevant
peptide (IRR). As a reference recipients were immunized with 2610
6 DCs matured with LPS and loaded with OVA peptide. OVA-specific T cells
(CD8
+CD45.2
+) were analyzed in the same mouse by surgical removal of superficial lymph nodes at d4 (effector) and d30–45 (memory) post-
immunization. Te and Tm cells were identified as CD8
+CD45.2
+ by flow cytometry. The percentage of Te and Tm cells generated are indicated on
each dot plot. B. Percentage of CD8
+ Te (left panel) and Tm (right panel) cells recovered at d4 (Te) and d.30 (Tm) in one lymph node is shown. C.
Yield of CD8
+ Tm cell generation. The yield of Tm cell formation was calculated as the percentage of Te cells that develop into Tm cells. D. The
percentage of mice that generates more then 5% of CD8
+ Tm cells is shown for the different immunization conditions. E and F. Lm challenges. 30 d
post immunization, mice were challenged with a lethal dose of Lm-OVA (10
5 CFU). 3 d post challenged, CFU were determined in the spleen (E) and
liver (F) for each mouse. A–D are from at least four independent experiments with at least two mice per group while E and F are from one
independent experiment with three mice per group. * p,0.05, ** p,0.01 and *** p,0.001.
doi:10.1371/journal.pone.0030139.g002
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did. These results show that TLR stimulation of CD40-B cells
enhanced their in vivo priming potential which leads to an
increased number of Ag-specific effectors but this was not sufficient
to promote CD8
+ Tm cell generation. Furthermore, we have
challenged a cohort of mice where Tm cell generation was below
the detection limit with Lm to confirm the lack of Tm generation.
Thirty days post-immunization with CD40-B LPS cells, mice were
not protected from Lm infection as shown by bacterial counts in
the spleen and liver (Figure 2E and F). Notwithstanding, the few
Tm cells that were generated in some experiments were functional
as shown by their rapid recall response when challenged with Ag-
pulsed DCs (Figure S4).
We have previously shown that the density of epitope presented
by DCs critically affects the yield of CD8
+ Tm cell generation [30].
Therefore, we have carefully compared the level of K
b-OVA
complexes at the surface of CD40-B cells and DCs. As shown, in
Figure S1 and S5, CD40-B cells express a higher density of epitope
than DCs. To definitively rule out that CD40-B cells were not
presenting enough Ag, we have immunized mice with CD40-B
cells loaded with more peptide and showed that this did not
ameliorate the formation of CD8
+ Tm cells (Figure S5).
CD40-B cells directly present Ag to CD8
+ T lymphocytes
in vivo
At the end of the culture, we obtained an almost pure
population of B cells (,95%) with few contaminating CD11c
+,
CD11b
+ and NK1.1
+ cells (less than 1–2% for each population).
To rule out the possibility that contaminating cells contributed to
the in vivo priming of OT-1 T cells, we sorted B cells from the
CD40-B LPS cell culture before immunization. The sorted and
unsorted CD40-B LPS cells were as efficient in generating CD8
+
Te cells at d4 post-immunization (Figure 3A). These results suggest
a direct priming of CD8
+ T cells by CD40-B LPS cells, but we
could not exclude that B cells were providing the OVA peptide to
endogenous APCs for cross-presentation. To rule out this
possibility, we used Bm1 mice which express a variant of the
MHC class I molecule H2-K
b. The H2-K
bm1 molecule has 3
amino acid substitutions in residues involved in peptide binding
and TCR interaction rendering this molecule unable to present
the OVA peptide to OT-1 T cells [31,32]. Therefore, APCs from
Bm1 mice are unable to cross-present the OVA peptide to the
transferred OT-1 T cells allowing us to test if CD40-B cells can
directly present the Ag and prime naı ¨ve CD8
+ T cells.
Unfortunately, this mutation is sufficient to induce rejection of
transferred OT-1 T cells within 2 to 3 days [33]. To bypass this
problem, we transferred into C57BL/6 or Bm1 mice 5610
6 CFSE
labeled OT-1 T cells in the morning followed by LPS-stimulated
CD40-B cell or DC immunization in the afternoon. CFSE dilution
2 d post-immunization in the spleen demonstrates that the Ag is
directly presented by the injected CD40-B cells (Figure 3B). All
OT-1 T cells in the Bm1 mice have proliferated, suggesting that
CD40-B cells can directly present Ag to naı ¨ve CD8
+ T cells.
CD40-B cell or DC vaccination generates similar effectors
To understand why CD40-B cell immunization does not lead to
memory generation, we have characterized Te cell phenotype. Te
cells generated following CD40-B cell or DC immunization have a
similar phenotype (Figure 4A and Figure S6). The level of
expression of CD44, CD62L, CD27, CD122 and 1B11 were
similar in the different groups indicating equivalent activation of
CD8
+ effectors following CD40-B cell or DC immunization
(Figure 4A). We observed a slightly lower expression of CD127
(IL-7 receptor a chain) by effectors generated following immuni-
zation with CD40-B cells compared to DCs. Since high level of
CD127 expression identifies the effectors that generate memory T
cells, we have further evaluated if there was a positive correlation
between the level of expression of CD127 and the yield of memory
T cells. As shown in Figure 4B, there is no correlation between
CD127 expression and the percentage of Tm cells generated for
both CD40-Bcell and DC immunizations. The lack of correlation is
notsurprisingsincemore than 75%of theeffectors have maintained
a high level of CD127 expression (Figure S7). Therefore, it is very
unlikely that the deficiency of Tm cell generation with CD40-B cell
vaccination is due to lower level of CD127. In our immunization
conditions, we did not obtain any increase in KLRG1 expression, a
marker used to identify short-lived effectors (SLECs) in inflamma-
tory models (not shown) [4,34]. Due to low inflammation, most of
ourTe cellsbear a MPECphenotype[4].Therefore,the cell surface
phenotype of effectors generated after B cell immunization does not
explain the poor generation of CD8
+ Tm cells.
To better characterize the potential of CD40-B cell vaccination,
we evaluated effector functions of OVA-specific CD8
+ T cells at
the peak of the response. Te cells generated after B cell or DC
immunization produce similar amounts of IL-2 (Figure 5 and
Figure S6). All types of immunization led to IFN-c production by
effectors but CD40-B CpG cell vaccination induces higher
Figure 3. CD40-B cells directly present Ag to naı ¨ve CD8
+ T cells.
A. Highly purified sorted CD40-B cells can induce a CD8
+ T cell response.
Mice were immunized as in Figure 2 with sorted or unsorted CD40-B
cells matured with LPS and loaded with OVA. Percentage of effectors
(CD8
+CD45.2
+) generated is shown at d4 post-immunization. B. Direct
priming of OVA-specific CD8
+ T cells by CD40-B cells. 5610
6 CFSE-
labelled OT-1 T cells were adoptively transferred into either C57BL/6 or
Bm1 recipients followed by immunization on the same day with 6610
6
LPS-treated CD40-B cells loaded with OVA (B LPS OVA) or an irrelevant
peptide (B LPS) or 2610
6 LPS-matured DCs loaded with OVA peptide
(DC OVA). The proliferation of OVA-specific T cells was analyzed 48 h
later. The histograms show CFSE-profile gated on OVA-specific CD8
+ T
cells using K
b-OVA tetramer staining. The percentage of undivided cells
is indicated on each histogram. 3 independent experiments with 2 mice
per group.
doi:10.1371/journal.pone.0030139.g003
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(Figure 5 and Figure S6). However, granzyme B production is
lower following CD40-B cell immunization (Figure 5 and Figure
S6) but this is only statistically significant for CD40-B LPS cell
immunization.
CD40-B cell immunization generates cytotoxic effectors
The lower level of granzyme B production by CD8
+ Te cells
obtained after CD40-B cell vaccination led us to evaluate their
ability to kill target cells in vivo. At d4 post-immunization, mice
were injected with OVA loaded target cells and specific lysis was
measured 4 h later. Te cells generated with CD40-B cell
vaccination have a reduced ability to kill target cells when
compared to the one obtained with DC immunization (Figure 6 A
and B). The reduced cytotoxic activity of Te cells generated after
CD40-B cell immunization could be a result of their lower
frequency when compared to DC immunization (Figure 2). Thus,
CD40-B cell immunization generates functional cytolytic effectors.
Effectors are able to control a bacterial infection
To further assess the functionality of Te cells following CD40-B
cell vaccination, we have measured their ability to control a Lm
Figure 4. Phenotype of the CD8
+ Te cells generated after CD40-B cell immunization. A. Phenotype of effectors at d4 post-immunization
with CD40-B cells treated or not with TLR ligands. Immunizations were realized as described in Figure 2 with CD40-B cells (2610
6) treated or not with
CpG or LPS and with DCs (2610
6) matured with LPS. The bar chart shows the MFI of expression for CD44, 1B11, CD127, CD122, CD27 by CD8
+ Te cells
(CD8
+CD45.2
+) normalized to the MFI of endogenous CD8
+ T cells (CD8
+CD45.2
2). For CD62L, the percentage of CD8
+ Te cells expressing high level of
CD62L is shown. B. No correlation between CD127 expression level and memory generation. The results are from 2 independent experiments for
CD27 and CD122 and from at least 3 independent experiments for the other cell surface molecules. * p,0.05, ** p,0.01 and *** p,0.001.
doi:10.1371/journal.pone.0030139.g004
Figure 5. Cytokine and granzyme B production by OVA-specific CD8
+ Te cells. Immunizations were realized as described in Figure 2 with
CD40-B cells (2610
6–6610
6) treated or not with CpG or LPS and with DCs (0.5610
5–2610
6) matured with LPS. The MFI ratio was determined as in
Figure 4A for IL-2, IFN-c and granzyme B production by CD8
+ Te cells at d4 post-immunization. Results are pooled from at least three independent
experiments with a minimun of 2 mice per group. * p,0.05, ** p,0.01 and *** p,0.001.
doi:10.1371/journal.pone.0030139.g005
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with one lethal dose of virulent Lm expressing OVA (Lm-OVA).
Immunization with both CD40-B LPS cells or DCs led to a 4 log
decrease in the spleen bacterial burden at d3 post-infection
(Figure 6C). Effectors generated with DC vaccination seem better
then those obtained with CD40-B cells to control Lm spreading in
the liver (Figure 6D). Again, we cannot rule out the possibility that
this is caused by the lower number of Te cells produced with
CD40-B cell immunization. Furthermore, both types of Te cells
expanded to the same extent following infection with Lm-OVA
indicating that CD40-B cells do not induce T cell tolerance (Figure
S8).
Enhanced contraction and reduced Bcl-6 expression by
effectors following CD40-B cell immunization
Our results clearly show that both DC and CD40-B cell
immunizations generate fully functional CD8
+ effectors and that
only Tm cell generation is impaired following CD40-B cell
vaccination. To further address why effectors generated with
CD40-B cell immunization did not differentiate into Tm cells, we
have evaluated the extent of T cell contraction. As shown in
Figure 7A, CD8
+ Te cells generated with CD40-B cell
immunization have a higher rate of contraction than the one
generated with DC immunization. Moreover, at day 10 post-
immunization, CD8
+ Te cells obtained with CD40-B cells were
already almost undetectable (Figure 7A). The enhanced contrac-
tion of effectors generated with CD40-B cell immunization is not
due to a lower expression of Bcl-2 (Figure 7B).
The transcriptional network controlling CD8
+ Tm cell
generation has been partially elucidated over the last years.
During CD8
+ T cell response to infection, the effectors (short-lived
effectors or SLECs) that will die by apoptosis expressed high level
of the transcription factor T-bet while MPECs express lower
amount of T-bet [4]. The level of expression of the transcription
factor Eomes inversely correlates with the level of T-bet suggesting
that high level of Eomes are necessary to promote MPEC
development and Tm cell formation [29,35,36]. Furthermore,
Eomes expression is needed for CD8
+ Tm cell self-renewal [37].
Similarly to T-bet, the transcriptional repressor Blimp-1 controls
the formation of SLECs and in its absence MPECs are
preferentially generated [38,39]. The transcriptional repressor
Bcl-6 is required for CD8
+ Tm cell generation but unlike T-bet,
Eomes and Blimp-1 it does not contribute to effector formation
[40,41]. Furthermore, Blimp-1 represses Bcl-6 expression allowing
for the differentiation of SLECs. Therefore, the balance of
expression of T-bet, Blimp-1, Eomes and Bcl-6 is crucial for
efficient development of CD8
+ Tm cells. To elucidate why CD40-
B cell immunization is not efficient to generate CD8
+ Tm cells, we
evaluated the expression level of these key transcription factors in
Te cells (CD8
+CD45.2
+) at the peak of the response (d4 post-
Figure 6. CD40-B cell vaccination generates functional effector. A. In vivo killing. Mice were immunized as in Figure 2. Four days post-
immunization, CFSE-labeled splenocytes pulsed or not with OVA were injected as target cells. After 4 h, the percentage of CFSE
hi (OVA-pulsed; gate
labeled OVA on the histogram) and CFSE
lo (unpulsed; gate labeled neg on the histogram) cells were analyzed in the spleen. Percentage of specific
lysis is indicated on the histogram and was calculated using the indicated gate and as described in Material and Methods. B. Percentage of specific
killing by OVA CD8
+ Te cells. Mean +/2 SEM of specific lysis are shown for the different immunization conditions. 2 mice per conditions, 3
independent experiments. C and D. Lm challenge. Four days post-immunization, mice were challenged with a lethal dose of Lm-OVA (10
5 CFU). 3 d
post-infection (peak of bacterial load), mice were killed and CFU were determined in the spleen (C) and the liver (D). Mean +/2 standard (SD) are
shown. 2–4 mice per conditions, 3 independent experiments. * p,0.05, ** p,0.01 and *** p,0.001.
doi:10.1371/journal.pone.0030139.g006
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Blimp-1 expression in Te cells generated with CD40-B LPS or DC
immunization (Figure 8). Moreover, effectors generated with
CD40-B cell immunization express higher amount of Eomes
(Figure 8), which should be beneficial for CD8
+ Tm cell generation
and self-renewal. These results suggest that CD8
+ Te cells that are
generated with CD40-B cell immunization are not more
terminally differentiated than the ones obtained with DC
immunization. However, we constantly observed a 25% reduction
in the level of expression of Bcl-6 in effectors obtained after CD40-
B cell immunization when compared to DC vaccination (Figure 8).
This suggests that CD40-B cells are unable to promote high level
of expression of Bcl-6, a key transcription factor involved in the
generation of CD8
+ Tm cells, and that this may leads to inefficient
differentiation of Te cells into memory cells.
Discussion
To better understand the signals given by different APCs, we
have compared CD8
+ T cell responses generated after CD40-B
cell or DC immunization. Our results clearly demonstrate that
CD40-B cells can present Ag and activate naı ¨ve CD8
+ T cells in
vivo. It is not surprising that CD40-B cells can act as efficient APCs
in vivo since CD40 stimulation leads to the up-regulation of MHC
class I and II molecules, CD80 and CD86 co-stimulatory
molecules allowing CD40-B cells to present Ag and provide
efficient co-stimulation to naı ¨ve CD8
+ T cells. Previous reports
have shown that B cells are tolerogenic APCs [6–12] but they used
small resting B cells lacking CD80 and CD86 expression, thus
explaining why no priming occurs. In our study, we have also
investigated if CD40-B cells directly present Ag to CD8
+ T cells or
if they only provide Ag for cross-presentation by endogenous
APCs. Using Bm1 mice as recipients for vaccination, we clearly
show that CD40-B cell directly act as APCs and that cross-
presentation by DCs is not necessary to induce a CD8
+ T cell
response. Therefore, CD40-B cells are good APCs to prime naı ¨ve
CD8
+ T cells in vivo opening the potential for their use in
vaccination.
When compared to DC, CD40-B cell vaccination generates 2
fold less effectors even after maturation with LPS or CpG. This
small difference is not a clinical issue since it could be easily
compensated by increasing the number of CD40-B cells used in
immunization. In fact, we have observed a similar expansion of
Ag-specific CD8
+ T cells when we used 3–4 times more CD40-B
cells than DCs (Figure S3). Increasing the number of CD40-B cells
in immunization is a relevant solution because it is very easy to
generate them in large numbers from small amounts of human
blood. Therefore, our results suggest that CD40-B cell immuni-
zation can be as good as DC immunization to generate Ag-specific
CD8
+ Te cells. Our results also show that further maturation of
CD40-B cells with TLR agonists, CpG or LPS, increases the
number of Ag-specific CD8
+ T cells generated. Therefore, in
vaccination protocols, it would be advantageous to activate CD40-
B cells with TLR agonists to increase effector generation.
Our results also show that CD40-B cell vaccination is able to
induce the proper differentiation of naı ¨ve CD8
+ T cells into
functional effectors. Only a minor difference was observed at the
functional level, effectors obtained with CD40-B LPS cell
immunization produce less granzyme B than the one obtained
with DC vaccination. Although producing less granzyme B, these
effectors were able to kill target cells in vivo. This indicates that
CD40-B cell vaccination is able to provide all the necessary signals
to generate cytolytic effectors. Furthermore, effectors generated
with CD40-B cell immunization expressed similar level of IFN-c
and IL-2 when compared to Ag-specific CD8
+ T cells obtained
with DC immunization. The production of IFN-c by effectors
obtained with CD40-B cell vaccination is very interesting since
IFN-c production correlates positively with clinically effective anti-
tumor response [42–52]. Moreover, Te cells generated with
CD40-B cell vaccination are able to control a Lm infection. Thus,
our results show that CD40-B cell immunization generates
functional effectors able to produce IFN-c, to kill target cells and
to control bacterial infection. Therefore, the ability of CD40-B cell
vaccination to produce potent effectors renders this approach of
interest to induce anti-tumor T cell response in cancer patients.
It is intriguing that CD40-B cell vaccination does not generate T
cell memory since most of the Te cells generated have a MPEC
phenotype (CD127
hiKLRG1
lo). The deficient Tm cell generation is
not due to the reduced number of effectors since decreasing the
numberofTe cells generatedwith DC immunization stilllead to the
formation of Tm cells (Figure S3). Therefore, the deficient Tm cell
generation suggests that priming with CD40-B cells does not
provide all the necessary signals to allow the differentiation of naı ¨ve
CD8
+ T cells into long-lived memory T cells. Further investigations
are needed to understand what is missing in CD40-B cells.
To better understand why CD40-B cell vaccination is not
efficient in promoting CD8
+ Tm cell generation, we evaluated the
Figure 7. Effectors generated with CD40-B cell immunization contract more rapidly than the one obtained with DC immunization.
A. Contraction of the OVA-specific CD8
+ T cell response. Mice were immunized as described in Figure 2. Lymph nodes were surgically removed at 4, 7,
10 and .30 days post-immunization. Cells were stained to determine the percentage of Te cells generated. The graph shows the percentage of
remaining Te cells (CD8
+CD45.2
+) over time relative to the peak of the response (d4). B. Effectors generated with CD40-B cell and DC immunization
express similar amount of Bcl-2 during the course of the CD8
+ T cell response. The MFI of Bcl-2 for OVA-specific CD8
+ Te cells was normalized to the
MFI of endogenous CD8
+ T cells to obtain a MFI ratio. 3 independent experiments. * p,0.05, ** p,0.01 and *** p,0.001.
doi:10.1371/journal.pone.0030139.g007
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transcription factors known to influence memory generation and
maintenance [4,29,35–39]. No differences were observed in the
expression of T-bet and Blimp-1 in Te cells obtained from CD40-
B cell and DC immunizations. Since the expression level of these
transcription factors control the fate between SLECs and MPECs
[29,35,36,38,39,53], our results suggest that Te cells generated
with CD40-B cell immunization are not more terminally
differentiated than the ones obtained with DC immunization
and that defective expression of these transcription factors are not
responsible for the poor memory generation that we observed with
CD40-B cell vaccination. Although effectors generated following
CD40-B cell immunization express higher level of Eomes they are
not able to differentiate into Tm cells suggesting that high level of
Eomes is not sufficient to promote CD8
+ Tm cell development.
However, Te cells generated with CD40-B cell immunization
express lower amount of the transcriptional repressor Bcl-6, known
to control CD8
+ Tm cell development [40,41], than effectors
generated with DC immunization. Therefore, it is possible that
this small (25%) reduction in Bcl-6 expression is responsible for the
poor development of CD8
+ Tm cells following CD40-B cell
vaccination. Further studies should reveal whether reduced Bcl-6
expression is solely responsible for the lack of CD8
+ Tm cell
generation or if improper induction of other transcription factors
contributes to defective formation of CD8
+ Tm cells with CD40-B
cell immunization.
In our hands, no protection was achieved when mice were
challenged with Lm at d30 post-immunization. This is in contrast
with the results of Vanden Bush et al [54] reporting successful
protection from Lm infection 30 d after CD40-B cell vaccination.
However, in their manuscript, they only look at protection and did
not enumerate the number of CD8
+ Tm cells generated. It is
possible that a very low number of CD8
+ Tm cells are generated
with CD40-B cell vaccination rendering their detection difficult.
However, it is very clear from our results that in some
experiments, but not all, CD8
+ Tm cells are generated and are
Figure 8. CD40-B cell immunization generates effectors expressing similar level of T-bet and Blimp-1, higher level of Eomes and
lower amount of Bcl-6. A. Expression of T-bet, Eomes and Bcl-6 by CD8
+ Te cells generated following CD40-B cell and DC immunizations. Four days
post-immunization with 2610
6 CD40-B cells or DCs matured with LPS and loaded with the OVA peptide, Te cells were stained intracellularily with
antibodies against T-bet, Eomes and Bcl-6 transcription factors. The representative overlay histogram shows expression of the transcription factor by
endogenous T cells (CD8
+CD45.2
2) and OVA-specific Te cells (CD8
+CD45.2
+). The MFI is shown on each overlay, the upper bold number indicates the
MFI of OVA-specific effectors (CD8
+CD45.2
+) while the lower number is for the endogenous population (CD8
+CD45.2
2). B. Quantification of the level
of expression of T-bet, Eomes and Bcl-6. The histograms shows the MFI of expression for T-bet, Eomes and Bcl-6 by OVA-specific CD8
+ Te cells
(CD8
+CD45.2
+) normalized to the MFI of endogenous CD8
+ T cells (CD8
+CD45.2
2). The results are from at least 2 independent experiments. C. Similar
expression of Blimp-1 by OVA-specific Te cells following CD40-B cell or DC immunization. At the peak of the response (d4), Te cells were sorted
(CD8
+CD45.2
+) from spleen to extract RNA. The relative expression of Blimp-1 was determined by quantitative RT-PCR. Expression relative to a
reference sample is shown. Results are from 4 independent experiments. * p,0.05 and *** p,0.001.
doi:10.1371/journal.pone.0030139.g008
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possible that mice will be protected from a Lm challenge when few
CD8
+ Tm cells are produced. The difference might also be
explained by the protocol used to generate CD40-B cells. Indeed,
Bishop’s team used CD40-B cells that spent only one day in
culture [54] while we used cells cultured for 4 days. We believe
that our protocol is closer to what is currently developed for
human B cell expansion [15,20]. Thus, it will be primordial to
determine if the culture regimen impacts the ability of CD40-B
cells to activate the immune system.
Although CD8
+ Tm cell generation is not optimal with CD40-B
cell vaccination such an approach might be viable in vaccination
strategy if a boosting regimen is included. Indeed, our preliminary
results suggest that it is possible to further re-expand the few Tm
cells that were generated in some experiments.
Understanding why CD40-B cell immunization does not
promote efficient CD8
+ Tm cell differentiation will help our
understanding of the mechanisms regulating CD8
+ Tm cell
generation and should allow for improvement of the APC
potential of CD40-B cells. Furthermore, the ability of CD40-B
cell vaccination to generate cytolytic effectors producing IFN-c
might be very beneficial for therapeutic vaccination.
Supporting Information
Figure S1 Characterization of CD40-B cells. A. Phenotype
of CD40-B cells and DCs. B cells were grown from B6SJL
splenocytes on irradiated murine NIH-3T3 fibroblasts transfected
with the mouse CD40L cDNA. After 3 days of culture, B cells
were matured with LPS (1 mg/mL) or CpG-DNA (2 mM) for
24 h. Freshly isolated splenocytes were also stained as controls.
Dendritic cells (DC) were obtained by culturing bone marrow cells
during 7 days with GM-CSF and IL-4 and were matured with LPS
(1 mg/mL) on day 6. Percentage of CD19
+ cells, percentage of
CD11c
+ cells or mean fluorescence intensity are indicated on each
histogram. CD86, CD80, IA
b,K
b, and CD62L histograms were
gated on CD19
+ cells for CD40-B cells and splenocytes or on
CD11c
+ cells for DCs. B. Similar loading of the OVA peptide for
each B cell culture conditions. SIINFEKL (OVA) peptide (4 mg/
ml) was added on day 3 of culture. The Kb-OVA complex was
detected using a monoclonal antibody (25.D1.16) that specifically
recognizes this peptide-MHC complex. The staining for K
b-OVA
is shown for each culture conditions.
(TIF)
Figure S2 Immunization with CD40-B lymphocytes
induces an endogenous response. C57BL/6 mice were
immunized with 2610
6 CD40-B cells or DCs matured with LPS
(1 mg/mL) and loaded with SIINFEKL (OVA) peptide. Responses
were measured in the blood 7 days post-immunization with K
b-
OVA tetramer staining. A. Representative dot plot are shown.
Cells were previously gated on CD8
+CD3
+ cells. B. Percentage of
response for each immunized mouse is shown. 2 independent
experiments. Statistical analysis was done using a t-test. *p,0.05
and **p,0.01.
(TIF)
Figure S3 Immunization with CD40-B cells can gener-
ate an effector response comparable to immunization
with DCs. 10
6 female OT-1 cells were adoptively transferred into
B6SJL female mice followed by immunization with 2610
6 or
6610
6 CD40-B cells, matured with LPS (1 mg/mL) or CpG-DNA
(2 mM) and loaded with 4 mg/mL of SIINFEKL (OVA) peptide.
As a reference recipients were immunized with 0.5610
6 or 2610
6
DCs matured with LPS and loaded with OVA peptide. OVA-
specific T cells (CD8
+CD45.2
+) effector response was analyzed in
the same mouse by surgical removal of superficial lymph nodes at
d4 and d30 or more. A. Percentage of Te cells (CD8
+CD45.2
+)
generated with 6610
6 (6 M) CD40-B LPS OVA, 6 M CD40-B
CpG OVA or 2610
6 (2 M) DC LPS OVA immunization. B.
Percentage of Te cells (CD8
+CD45.2
+) obtained with 2 M CD40-
B LPS OVA, 2 M CD40-B CpG OVA or 0.5610
6 (0.5 M) DC
LPS OVA immunization. C. Percentage of Tm cells
(CD8
+CD45.2
+) generated following immunization with 2 M
CD40-C CpG OVA, 2 M CD40-B LPS OVA or 0.5 M DC
LPS OVA. D. Memory yield (% of Tm cells generated from Te
cells) is shown for the different immunization conditions (as in B).
Each dot represents one mouse. Medians are shown and Kruskall-
Wallis statistical analysis was performed. ** p,0.01, *** P,0.001.
(TIF)
Figure S4 Recall response of CD8
+ memory T cells after
a challenge with Ag-pulsed DCs. 10
6 female OT-1 T cells
(CD8
+CD45.2
+) were adoptively transferred into congenic B6SJL
female mice (CD45.1
+) followed by immunization two days later
with 2610
6 CD40-B cells, matured or not with LPS (1 mg/mL) or
CpG (2 mM) and loaded with 4 ug/mL of OVA peptide or with
an irrelevant peptide (IRR). As a reference recipients were
immunized with 2610
6 DCs matured with LPS and loaded with
OVA peptide. The presence of OVA-specific T cells
(CD8
+CD45.2
+) were analyzed in the same mouse by surgical
removal of superficial lymph nodes at d4 (effector; top row) and
d44 (memory; middle row) of the primary response. At d45 post-
immunisation, mice were challenged or not with 1.25610
6 DCs
matured with LPS and pulsed with the OVA peptide. Three days
(d48) post-challenge, mice were sacrificed and OVA specific CD8
+
memory T cell (CD8
+CD45.2
+) expansion was evaluated in the
lymph nodes (bottom row).
(TIF)
Figure S5 Defective memory T cell generation with
CD40-B cell vaccination is not due to lower epitope
density. A. CD40-B cells express a higher density of epitope than
DCs. The level of K
b-OVA MHC-peptide complex expressed by
the different APCs was evaluated using a monoclonal antibody
(25.D1.16) that specifically recognizes this peptide-MHC complex.
The staining for K
b-OVA is shown for each APC type used for
immunization. The mean fluorescence intensity of K
b-OVA
expression is indicated for each APC type next to the legend. B.
Increasing epitope density on CD40-B cells does not improve the
generation of CD8
+ memory T cells. 10
6 female OT-1 T cells
(CD8
+CD45.2
+) were adoptively transferred into congenic B6.SJL
female mice (CD45.1
+) followed by immunization two days later
with 2610
6 CD40-B cells, matured with LPS (1 mg/mL) and
loaded with different concentrations of OVA peptide (4 or 10 mg/
ml) or with an irrelevant peptide (IRR). As a reference recipients
were immunized with 2610
6 DCs matured with LPS and loaded
with 2 mg/ml of OVA peptide. The dot plots show the effector (d4)
and memory responses (d32) for each vaccination conditions. The
percentage of effector and memory (CD8
+CD45.2
+) T cells
generated are indicated on each dot plot.
(TIF)
Figure S6 Phenotype and function of effector CD8
+ T
cells generated after CD40-B cell immunization. A.
Phenotype of OVA-specific CD8
+ effector T cells. 10
6 female
OT-1 cells were adoptively transferred into B6SJL female mice
followed by immunization with 2610
6 CD40-B cells, matured or
not with LPS (1 mg/mL) or CpG-DNA (2 mM) and loaded with
4 mg/mL SIINFEKL (OVA) or an irrelevant peptide (IRR). As a
reference recipients were immunized with 2610
6 DCs matured
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tion, lymph nodes were removed by surgery and the phenotype of
effectors was analysed by flow cytometry. The overlays show
expression of the different cell surface markers by OVA-specific T
cells (CD8
+CD45.2
+) compared to endogenous T cells
(CD8
+CD45.2
2). The mean fluorescence intensity (MFI) is
indicated on each histogram, the upper bold number indicates
the MFI of OVA-specific effectors (CD8
+CD45.2
+) while the lower
number is for the endogenous population (CD8
+CD45.2
2). B.
Acquisition of effector functions by OVA-specific CD8
+ T cells
following CD40-B cell vaccination. OVA-specific effector CD8
+ T
cells were generated as in A. 4 days post-immunization, cells were
restimulated for 4 h with PMA/ionomycin in the presence of
brefeldin A to evaluate IFN-c, IL-2 and granzyme B production.
The overlays show production of the different effector molecules
by OVA-specific T cells (CD8
+CD45.2
+) compared to endogenous
T cells (CD8
+CD45.2
2). The MFI is indicated on each histogram,
the upper bold number indicates the MFI of OVA-specific
effectors (CD8
+CD45.2
+) while the lower number is for the
endogenous population (CD8
+CD45.2
2).
(TIF)
Figure S7 The majority of effectors generated with
CD40-B cell immunization express high level of CD127.
10
6 female OT-1 cells were adoptively transferred into B6SJL
female mice followed by immunization with 2610
6 CD40-B cells
or DCs matured with LPS (1 mg/mL) and loaded with SIINFEKL
(OVA). OVA-specific T cells (CD8
+CD45.2
+) effectors response
was analyzed in superficial lymph nodes at d4 post-immunization.
Percentage of effectors highly expressing CD127 are shown. 3
independent experiments, 2–3 mouse per experiments.
(TIF)
Figure S8 Similar CD8+ effector T cell expansion
following Listeria monocytogenes challenge. 10
6 female
OT-1 T cells (CD8
+CD45.2
+) were adoptively transferred into
congenic B6SJL female mice (CD45.1
+) followed by immunization
two days later with 2610
6 CD40-B cells, matured or not with LPS
(1 mg/mL) and loaded with 4 mg/mL OVA or with an irrelevant
peptide (IRR). As a reference recipients were immunized with
5610
5 DCs matured with LPS and loaded with OVA peptide.
Four days post-immunization, mice were challenged with a lethal
dose of Lm-OVA (10
5 CFU). On the day of challenge and 3 d
post-infection (peak of bacterial load) blood was harvested, stained
and analyzed by flow cytometry. Percentage of CD8
+CD45.2
+
effectors before and after challenge were determined to calculate
fold expansion. Mean +/2 SEM are shown. 2–4 mice per
conditions, 3 independent experiments. * p,0.05 and ** p,0.01.
(TIF)
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